National MS Society Invests in Commercial Research by Longevity Biotech for Development of a Neuroprotective/Repair Treatment for Progressive MS
November 3, 2017
The National MS Society, through Fast Forward, is investing up to $316,384 to enable Longevity Biotech, Inc. to evaluate LBT-3627 in laboratory models as a potential disease-modifying therapeutic agent for progressive multiple sclerosis. The program aims to determine the ability of LBT-3627 to protect and repair damaged nerve cells while also restoring balance to the immune system.
This investment stemmed from a request for proposals released by Fast Forward for projects focused on testing existing therapies or drug candidates to determine if they protect the nervous system from damage and/or repair damage, especially for the treatment of progressive MS.
“These preclinical studies may provide evidence for further development of LBT-3627 for progressive forms of MS.” said Mark Allegretta, PhD, Associate Vice President of Commercial Research at the National MS Society. “LBT-3627 has neuroprotective qualities and part of this work will determine its ability to promote maturation of myelin-producing cells.”
LBT-3627 is also in development for Parkinson’s disease among other neurological disorders.
Read more about Fast Forward
Read more about research in progressive MS